GZR101 vs GZR33
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
GZR101
Developed by Gan & Lee Pharmaceuticals
NCT06199505 · Phase 2 · completed
The study used randomization and an active comparator, but it was open-label and had a surrogate primary endpoint—change in HbA1c rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT07387003 (registry estimate)
Reported efficacy
Change in HbA1c (Baseline to week 16): Change in HbA1c from baseline to week 16: Part A GZR101 once-daily -1.56% vs IDegAsp once-daily -1.31% (difference -0.24%); Part B GZR101+aspart once-daily -1.64% and twice-daily -1.68% vs IDegAsp twice-daily -1.59% (differences -0.06% and -0.09%). (met)
Result source: NCT06199505
GZR33
Developed by Gan & Lee Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | GZR101 | GZR33 |
|---|---|---|
| HbA1c, change | -1.6% vs -1.3%avs IDegAsp once-dailyNCT061995052 other results
| —Trial running · NCT07527078 |
| Body weight, change (kg) | —Not reported | —Trial running · NCT07527078 |
| HbA1c below 7% | —Not reported | —Trial running · NCT07527078 |
| Fasting plasma glucose, change | —Not reported | —Trial running · NCT07527078 |
| 3-point MACE (% with event) | —Not reported | —Trial running · NCT07527078 |
HbA1c, change
- GZR101
- -1.6% vs -1.3%avs IDegAsp once-dailyNCT06199505
2 other results
- -1.6% vs -1.6% NCT06199505
- -1.7% vs -1.6% NCT06199505
- GZR33
- —Trial running · NCT07527078
Body weight, change (kg)
- GZR101
- —Not reported
- GZR33
- —Trial running · NCT07527078
HbA1c below 7%
- GZR101
- —Not reported
- GZR33
- —Trial running · NCT07527078
Fasting plasma glucose, change
- GZR101
- —Not reported
- GZR33
- —Trial running · NCT07527078
3-point MACE (% with event)
- GZR101
- —Not reported
- GZR33
- —Trial running · NCT07527078
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
GZR33: no structured comparison results are available for Type 2 Diabetes.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
GZR101
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GZR101's landscape · GZR33's landscape